High
Excellent
Empiric therapy
UTI/Pyelonephritis
Bronchitis
CAP and COPD exacerbation (NON-ICU patients)
Note: per BMH policy Levaquin will be automatically interchanged for the above indications
Lab
SCr
LFTs with prolonged use
Clinical
Hypersensitivity
Monitor QTc in patients with increased risk
GI effects
Drug interactions (warfarin)
tendonitis
QTc prolongation
Dysglycemia
Rash
Tendinopathy and rupture
GI upset
Weakness exacerbation in myasthenia gravis
CNS toxicity including confusion, psychosis
Other QTc prolonging agents
Divalent cations - Decreased absorption
NSAIDs - Increase seizure risk
Warfarin - Increased INR
Fluoroquinolones are associated with disabling and potentially irreversible serious adverse reactions that may occur together, including tendinitis and tendon rupture, peripheral neuropathy, and CNS effects. Discontinue levofloxacin immediately and avoid use of fluoroquinolones in patients who experience any of these serious adverse reactions.
Antimicrobial class: Fluoroquinolone
Pregnancy category: C
Average serum half life: 7 hours
Urine penetration: Therapeutic
Lung penetration: Therapeutic
Biliary penetration: Therapeutic